Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG
Evaluation of an Artificial Intelligence-Enhanced Electrocardiogram Strategy Versus Standard Care to Identify Patients Requiring Cardiac Implantable Electronic Devices: A Randomized Controlled Trial
National Defense Medical Center, Taiwan
11,492 participants
Nov 1, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable electronic devices (CIEDs), compared with standard clinical care.
Eligibility
Inclusion Criteria1
- At least one 12-lead ECG within 1 year
Exclusion Criteria5
- Diagnosis of sick sinus syndrome
- Diagnosis of high-grade or complete atrioventricular block
- Diagnosis of ventricular tachycardia or ventricular fibrillation
- Post CIED implant
- Heart rate below 40 beats per minute by 12-lead ECG
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants identified as high-risk for CIED implantation by the AI-ECG system will receive a continuous cardiac rhythm monitor for up to 7 days.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07217236